Evaxion Biotech A/S ADR (NASDAQ:EVAX) does about 1.07M shares in volume on a normal day but saw 3279597 shares change hands in the recent trading day. The company now has a market cap of 7.02M USD. Its current market price is $6.00, marking a decrease of -0.50% compared to the previous close of $6.03. The 52 week high reached by this stock is $53.45 whilst the lowest price level in 52 weeks is $2.38.
Evaxion Biotech A/S ADR (EVAX) has a 20-day trading average at $4.23 and the current price is -88.77% off the 52-week high compared with 152.10% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.78 and its 200-day simple moving average is $13.40. If we look at the stock’s price movements over the week, volatility stands at 55.35%, which decreases to 23.65% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 59.72 to suggest the stock is neutral.
The consensus objective for the share price is $41.58, suggesting that the stock has a potential upside of 85.57% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 02, 2024 when Ladenburg Thalmann upgraded the stock to “Buy” and issued a price target of $8.
The current price level is 41.97%, 3.73%, and -55.22% away from its SMA20, SMA50, and SMA200 respectively, with the EVAX price moving above the 50-day SMA on current market day. Evaxion Biotech A/S ADR (EVAX) stock is up 94.17% over the week and 32.20% over the past month. Its price is 41.94% year-to-date and -88.73% over the past year.
To reach the target analysts have set, the stock logically needs to grow 85.57 percent from here.
Outstanding shares total 1.17M with insiders holding 9.24% of the shares and institutional holders owning 10.27% of the company’s common stock. The company has a return on investment of -102.11% and return on equity of -803.07%. The beta has a value of -0.09. Price to book ratio is 5.18 and price to sales ratio is 2.13.
